Skip to main content
padlock icon - secure page this page is secure

Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome

Buy Article:

$68.00 + tax (Refund Policy)

Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATPmediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 5-HT; Bifidobacterium; Bifidobacterium strains; CNS; Crohn's disease; Dexamethasone; Gastroenterology; IB; IBS prevalence; IL-6; IL-8; Irritable bowel syndrome; Lactobacillus; Streptococcus; acetylcholine; antidepressants; antispasmodics; chemokines; cholecystokinin; chronic gastrointestinal disorder; cimetropium; clinical trials; corticotropin-releasing factor; dopamine; drug development; enteric nervous system; functional bowel disorders; gastrointestinal tract; immune modulation; inflammation; inflammatory bowel disease; interferon gamma; interleukin-6; lactose intolerance; macrolide; mebeverine; monoclonal antibodies; neurotransmitter; occludin; otilonium; pinaverium; polyethylene glycol; proteasomes; serotonin reuptake inhibitors; serotonin reuptake transporter; tegaserod; tricyclic antidepressants; tryptophan hydroxylase

Document Type: Research Article

Publication date: November 1, 2010

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more